{"filing":{"accession_number":"0001193125-26-338273","cik":"0001660334","ticker":"VRCA","company_name":"Verrica Pharmaceuticals Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"d13828d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1660334/000119312526338273/d13828d8k.htm"},"events":[{"id":24601,"run_id":22304,"accession_number":"0001193125-26-338273","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard earnings release disclosing Verrica's financial results for Q2 2026 and six months ended June 30, 2026. The press release (Exhibit 99.1) reports total revenue of $5.9 million in Q2 2026, U.S. YCANTH net product revenue of $5.1 million, and a net loss of $13.2 million for the quarter. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings disclosures.","company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":25218,"accession_number":"0001193125-26-338273","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Verrica's financial results for Q2 2026 and six months ended June 30, 2026. The press release (Exhibit 99.1) reports total revenue of $5.9 million in Q2 2026, U.S. YCANTH net product revenue of $5.1 million, and a net loss of $13.2 million for the quarter. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:19:15.127350+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25218,"accession_number":"0001193125-26-338273","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard earnings release disclosing Verrica's financial results for Q2 2026 and six months ended June 30, 2026. The press release (Exhibit 99.1) reports total revenue of $5.9 million in Q2 2026, U.S. YCANTH net product revenue of $5.1 million, and a net loss of $13.2 million for the quarter. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-07T00:19:15.127350+00:00","company_name":"Verrica Pharmaceuticals Inc.","ticker":"VRCA","filing_date":"2026-08-06"}]}